Possibility and challenge of cancer therapy using combination products with drug and device-insight from experiences of investigator-initiated clinical trial for malignant brain tumors by photodynamic therapy using talaporfin and PDT laser

Yoshihiro Muragakı, Takashi Maruyama, Soko Ikuta, Jiro Akimoto, Masanori Maeda, Hiroshi Iseki

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In modern medicine, many numbers and kinds of combination products have increased dramatically. Typical examples of combination products are a drug-eluting stent, a bactiseal catheter, and a photodynamic therapy for cancer treatments. The photodynamic therapy is a minimally invasive, and double targeting therapy that we inject a photosensitizer targeting cancer cells and irradiate a laser around or to the cancer locally. In 2007, we started an investigator-initiated clinical trial of the photodynamic therapy using a Talaporfin and a laser, to expand indication of malignant brain tumors in addition to early lung cancers. In 2013, Ministry of Health, Labour and Welfare has approved the photodynamic therapy for malignant brain tumors. We here describe the experiences of the trial and the future direction about another combination product of a sonodynamic therapy using a drug and a focused high-intensity ultrasound.

Original languageEnglish
Pages (from-to)226-233
Number of pages8
JournalDrug Delivery System
Volume30
Issue number3
DOIs
Publication statusPublished - 2015 Oct 25
Externally publishedYes

Fingerprint

Photochemotherapy
Brain Neoplasms
Lasers
Research Personnel
Clinical Trials
Equipment and Supplies
Pharmaceutical Preparations
Neoplasms
Modern 1601-history
Drug-Eluting Stents
Photosensitizing Agents
Therapeutics
Lung Neoplasms
Catheters
1-phenyl-3,3-dimethyltriazene
Talaporfin
Health

Keywords

  • NPe6
  • Photodynamic therapy
  • Sonodynamic therapy

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Possibility and challenge of cancer therapy using combination products with drug and device-insight from experiences of investigator-initiated clinical trial for malignant brain tumors by photodynamic therapy using talaporfin and PDT laser. / Muragakı, Yoshihiro; Maruyama, Takashi; Ikuta, Soko; Akimoto, Jiro; Maeda, Masanori; Iseki, Hiroshi.

In: Drug Delivery System, Vol. 30, No. 3, 25.10.2015, p. 226-233.

Research output: Contribution to journalArticle

@article{477e4e2b13e247f1a65f0b52b971254d,
title = "Possibility and challenge of cancer therapy using combination products with drug and device-insight from experiences of investigator-initiated clinical trial for malignant brain tumors by photodynamic therapy using talaporfin and PDT laser",
abstract = "In modern medicine, many numbers and kinds of combination products have increased dramatically. Typical examples of combination products are a drug-eluting stent, a bactiseal catheter, and a photodynamic therapy for cancer treatments. The photodynamic therapy is a minimally invasive, and double targeting therapy that we inject a photosensitizer targeting cancer cells and irradiate a laser around or to the cancer locally. In 2007, we started an investigator-initiated clinical trial of the photodynamic therapy using a Talaporfin and a laser, to expand indication of malignant brain tumors in addition to early lung cancers. In 2013, Ministry of Health, Labour and Welfare has approved the photodynamic therapy for malignant brain tumors. We here describe the experiences of the trial and the future direction about another combination product of a sonodynamic therapy using a drug and a focused high-intensity ultrasound.",
keywords = "NPe6, Photodynamic therapy, Sonodynamic therapy",
author = "Yoshihiro Muragakı and Takashi Maruyama and Soko Ikuta and Jiro Akimoto and Masanori Maeda and Hiroshi Iseki",
year = "2015",
month = "10",
day = "25",
doi = "10.2745/dds.30.226",
language = "English",
volume = "30",
pages = "226--233",
journal = "Drug Delivery System",
issn = "0913-5006",
publisher = "Japan Society of Drug Delivery System",
number = "3",

}

TY - JOUR

T1 - Possibility and challenge of cancer therapy using combination products with drug and device-insight from experiences of investigator-initiated clinical trial for malignant brain tumors by photodynamic therapy using talaporfin and PDT laser

AU - Muragakı, Yoshihiro

AU - Maruyama, Takashi

AU - Ikuta, Soko

AU - Akimoto, Jiro

AU - Maeda, Masanori

AU - Iseki, Hiroshi

PY - 2015/10/25

Y1 - 2015/10/25

N2 - In modern medicine, many numbers and kinds of combination products have increased dramatically. Typical examples of combination products are a drug-eluting stent, a bactiseal catheter, and a photodynamic therapy for cancer treatments. The photodynamic therapy is a minimally invasive, and double targeting therapy that we inject a photosensitizer targeting cancer cells and irradiate a laser around or to the cancer locally. In 2007, we started an investigator-initiated clinical trial of the photodynamic therapy using a Talaporfin and a laser, to expand indication of malignant brain tumors in addition to early lung cancers. In 2013, Ministry of Health, Labour and Welfare has approved the photodynamic therapy for malignant brain tumors. We here describe the experiences of the trial and the future direction about another combination product of a sonodynamic therapy using a drug and a focused high-intensity ultrasound.

AB - In modern medicine, many numbers and kinds of combination products have increased dramatically. Typical examples of combination products are a drug-eluting stent, a bactiseal catheter, and a photodynamic therapy for cancer treatments. The photodynamic therapy is a minimally invasive, and double targeting therapy that we inject a photosensitizer targeting cancer cells and irradiate a laser around or to the cancer locally. In 2007, we started an investigator-initiated clinical trial of the photodynamic therapy using a Talaporfin and a laser, to expand indication of malignant brain tumors in addition to early lung cancers. In 2013, Ministry of Health, Labour and Welfare has approved the photodynamic therapy for malignant brain tumors. We here describe the experiences of the trial and the future direction about another combination product of a sonodynamic therapy using a drug and a focused high-intensity ultrasound.

KW - NPe6

KW - Photodynamic therapy

KW - Sonodynamic therapy

UR - http://www.scopus.com/inward/record.url?scp=84945258797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945258797&partnerID=8YFLogxK

U2 - 10.2745/dds.30.226

DO - 10.2745/dds.30.226

M3 - Article

AN - SCOPUS:84945258797

VL - 30

SP - 226

EP - 233

JO - Drug Delivery System

JF - Drug Delivery System

SN - 0913-5006

IS - 3

ER -